NCT06212102 Dydrogesterone Versus GnRH Antagonist in Poor Responders Undergoing Double Ovarian Stimulation
| NCT ID | NCT06212102 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Bedaya Hospital |
| Condition | Infertility |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2024-05-08 |
| Primary Completion | 2027-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 120 participants in total. It began in 2024-05-08 with a primary completion date of 2027-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this randomized controlled trial is to compare the efficacy and cost-effectiveness of using progestin with GnRH antagonist to prevent premature LH surge in poor responders undergoing double stimulation protocol.
Eligibility Criteria
Inclusion Criteria: Patients belonging to Poseidon group 4 Exclusion Criteria: * PCOS * Endometriosis * History of recurrent abortion
Contact & Investigator
Samar A Alhofy, M.D, Msc
PRINCIPAL INVESTIGATOR
Cairo University
Frequently Asked Questions
Who can join the NCT06212102 clinical trial?
This trial is open to female participants only, aged 35 Years or older, up to 44 Years, studying Infertility. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06212102 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06212102 currently recruiting?
Yes, NCT06212102 is actively recruiting participants. Contact the research team at umfrfouda@yahoo.com for enrollment information.
Where is the NCT06212102 trial being conducted?
This trial is being conducted at Cairo, Egypt, Giza, Egypt.
Who is sponsoring the NCT06212102 clinical trial?
NCT06212102 is sponsored by Bedaya Hospital. The principal investigator is Samar A Alhofy, M.D, Msc at Cairo University. The trial plans to enroll 120 participants.